Mark Lewis: Median OS for SCLC approach the conventional 5-year milestone

Mark Lewis shared on X/Twitter:

”Not every day that you get to celebrate a years-long survival advantage in the treatment of small cell lung cancer!!!

Mind-blowing to see the median overall survival for limited stage SCLC approach the oncologically conventional 5-year milestone.”

Source: Mark Lewis/X

Mark Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.